DERM Stock Analysis: Buy, Sell, or Hold?
DERM - Journey Medical Corporation Common Stock
$5.03
0.03 (0.60%)
▲
5d:
-3.08%
30d:
-3.08%
90d:
-39.76%
BUY
MODERATE Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 13, 2026
4d
Get Alerted When DERM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DERM this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 41.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: DERM shows positive signals but monitor for confirmation. Market pricing in 41.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$48.15
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$29.90
83.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DERM is currently trading at $5.03, which is considered fair relative to its 30-day fair value range of $4.86 to $5.30. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.9) compared to its historical average (24.3). Remarkably, the market is currently pricing in an annual earnings decline of 41.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DERM is in a strong downtrend. Immediate support is located at $4.84, while resistance sits at $5.39.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.50 (+170.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DERM is in a strong downtrend. Immediate support is located at $4.84, while resistance sits at $5.39.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.50 (+170.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.86 -
$5.30
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 170.0% below Wall St target ($13.50)
Trading Range Analysis
30-Day Trading Range
$4.86 -
$5.30
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.84
Resistance Level
$5.39
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.91
Wall Street Target
$13.50
(+170.0%)
Revenue Growth (YoY)
18.1%
Profit Margin
-18.5%
Valuation Discount vs History
-41.3% cheaper
PE vs Historical
4.9 vs 24.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-41.3%
(market-implied from PE analysis)
1-Year Target
$4.50
(-10%)
2-Year Target
$4.05
(-19%)
3-Year Target
$3.65
(-27%)
3-Yr Target (if PE normalizes)
(PE: 5→24)
$18.02
(+261%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 1303.4%)
$75.34
(+1407%)
Base:
(SPY PE: 4.9, Growth: 1303.4%)
$16.88
(+238%)
Bear:
(PE: 4.2, Growth: 1303.4%)
$14.34
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.9 to 24.3
Stabilization Target:
$24.73
(+394.5%)
PE Expansion Potential:
+394.5%
Share & Embed Analysis
Last updated: May 08, 2026 1:45 PM ET
Data refreshes hourly during market hours. Next update: 2:45 PM
Data refreshes hourly during market hours. Next update: 2:45 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DERM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$186 | 63 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$96 | 66 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$149 | 53 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 57 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 60 HOLD |
